Melanoma

Checkmate Pharmaceuticals is conducting studies of vidutolimod (CMP-001) in combination with nivolumab for the treatment of advanced, PD-1 refractory melanoma and first-line (PD-1-naïve) melanoma. Melanoma is a serious form of skin cancer that arises from a particular skin cell type called a melanocyte. This form of skin cancer is particularly dangerous because of its ability to rapidly spread to other organs if not surgically removed at an early stage, as well as its low response rates and limited durability of response when treated with commonly used chemotherapeutics. Melanoma of the skin accounts for approximately 1% of all skin cancers in the U.S., according to the American Cancer Society, which estimates 106,110 new diagnoses and approximately 7,180 deaths as a result of melanoma in the United States in 2021.

Enrolling

CMP-001-010:
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Identifier: NCT04698187
A Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.

Clinical Trial Overview

The study is designed to determine confirmed objective response rate (ORR) for treatment with vidutolimod in combination with nivolumab in participants with refractory unresectable or metastatic melanoma.

To learn more about this clinical trial or to view a list of active trial site locations, please visit:

CMP-001-011:
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Identifier: NCT04695977
A Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.

Clinical Trial Overview

The study is divided into two phases: Phase 2 and Phase 3.

The Phase 2 study is designed to determine confirmed objective response rate (ORR) for treatment with first-line vidutolimod in combination with nivolumab versus nivolumab monotherapy in participants with unresectable or metastatic melanoma.

The Phase 3 study is designed to evaluate progression-free survival (PFS) for subjects receiving first-line vidutolimod in combination with nivolumab versus nivolumab monotherapy for unresectable or metastatic melanoma.

To learn more about this clinical trial or to view a list of active trial site locations, please visit:


Vidutolimod is an investigational immunotherapy being evaluated in clinical studies and has not been approved by the FDA or any other agency. Clinical trials are designed to evaluate the safety and efficacy of investigational therapies. Please consult your doctor about your eligibility and the benefits and risks of participating in our trials.